The 13th Annual BIO Investor Forum

BIO Investor Forum 
October 7-8, 2014

To register, click here.

To view the 2014 Presenting Companies, click here.
To view the list of attending investment firms, click here.

Join our next web panel Oct. 1 at 11am PDT: "How to Pitch to Investors"

Request a free recording of the webinar, "What's Hot and What's Not in Oncology Licensing" 

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One PartneringTM meetings.

BIO One-on-One PartneringTM provides an opportunity to arrange meetings between investors; companies; and industry BD, licensing and therapeutic franchise heads. 

Download the BIF eBrochure

Download the 2014 Program Schedule

BIO Investor Forum Statistics

  • 71% of all U.S. therapeutic companies that have had an IPO in 2013 have attended the BIO Investor Forum at least once in the past four years.
  • Last year’s conference scheduled more than 900 meetings.
  • Nearly 80% of all requests were between biotech companies and investors.
  • The event hosted 120 late-stage private and emerging public company presentations.
  • 34% of all U.S. therapeutic IPO companies since 2012 attended BIO Investor Forum as a private company.

 

What People are Saying About the BIO Investor Forum

"For us, the BIO Investor Forum is the bellwether of life science investing and business creation. As such, it's the "must go to" meeting on our calendar each year." - Graeme Martin, CEO, Takeda Ventures

“The BIO Investor Forum over the years has proved to be an excellent venue for investors to interact with a high quality group of emerging biotechnology companies and their senior management teams.  The ongoing exposure to the investor community is invaluable to this group of companies as they execute their business strategies, achieve significant clinical catalysts and ultimately look to the capital markets to fund their continued advancement.  Given my experience over the years, I have found this well-orchestrated conference to be a “must-attend” annual event.” - John Chambers, ROTH Capital Partners